Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Option Care Health (OPCH)

Tipranks - Thu Feb 26, 7:32AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tarsus Pharmaceuticals (TARSResearch Report) and Option Care Health (OPCHResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Tarsus Pharmaceuticals (TARS)

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Tarsus Pharmaceuticals on February 23 and set a price target of $105.00. The company’s shares closed last Tuesday at $75.01.

According to TipRanks.com, Argyrides is a 4-star analyst with an average return of 10.3% and a 43.2% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, MoonLake Immunotherapeutics, and Aquestive Therapeutics. ;'>

Tarsus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $91.57, implying a 22.8% upside from current levels. In a report released yesterday, TipRanks – DeepSeek also upgraded the stock to Buy with a $77.00 price target.

See today’s best-performing stocks on TipRanks >>

Option Care Health (OPCH)

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Option Care Health, with a price target of $40.00. The company’s shares closed last Tuesday at $33.82, close to its 52-week high of $35.53.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 11.5% and a 59.3% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Option Care Health with a $38.88 average price target, which is a 15.9% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a $38.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.